Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig W Ritchie

Showing results (111-120 of 147) with videos related to

Pageof 15
Sort By:
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|May 3, 2023
Differential association of cerebral blood flow and anisocytosis in APOE ε4 carriers at midlifeMaria-Eleni Dounavi, Elijah Mak, Peter Swann, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2025
Hypothalamic volume, sleep, and APOE genotype in cognitively healthy adultsAxel A S Laurell, Elijah Mak, Maria-Eleni Dounavi, et al.
BMC Neurology|April 18, 2017
Big data and data repurposing - using existing data to answer new questions in vascular dementia researchFergus N Doubal, Myzoon Ali, G David Batty, et al.
Archives of Neurology|December 17, 2003
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trialCraig W Ritchie, Ashley I Bush, Andrew Mackinnon, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|April 27, 2022
Genome- and epigenome-wide studies of plasma protein biomarkers for Alzheimer's disease implicate TBCA and TREM2 in disease riskRobert F Hillary, Danni A Gadd, Daniel L McCartney, et al.
Alzheimer'S Research & Therapy|October 27, 2017
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.
Alzheimer'S Research & Therapy|October 12, 2022
Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia studyAudrey Low, Maria A Prats-Sedano, Elizabeth McKiernan, et al.
Nature Communications|July 20, 2019
Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936Robert F Hillary, Daniel L McCartney, Sarah E Harris, et al.
Alzheimer'S Research & Therapy|August 1, 2018
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 3, 2025
Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p-tau in the earliest Alzheimer's continuum: Evidence across two independent cohortsRaffaele Cacciaglia, Carles Falcón, Gonzalo Sánchez Benavides, et al.
Pageof 15

Showing results (111-120 of 147) with videos related to

Sort By:
Pageof 15
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|May 3, 2023
Differential association of cerebral blood flow and anisocytosis in APOE ε4 carriers at midlifeMaria-Eleni Dounavi, Elijah Mak, Peter Swann, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2025
Hypothalamic volume, sleep, and APOE genotype in cognitively healthy adultsAxel A S Laurell, Elijah Mak, Maria-Eleni Dounavi, et al.
BMC Neurology|April 18, 2017
Big data and data repurposing - using existing data to answer new questions in vascular dementia researchFergus N Doubal, Myzoon Ali, G David Batty, et al.
Archives of Neurology|December 17, 2003
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trialCraig W Ritchie, Ashley I Bush, Andrew Mackinnon, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|April 27, 2022
Genome- and epigenome-wide studies of plasma protein biomarkers for Alzheimer's disease implicate TBCA and TREM2 in disease riskRobert F Hillary, Danni A Gadd, Daniel L McCartney, et al.
Alzheimer'S Research & Therapy|October 27, 2017
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.
Alzheimer'S Research & Therapy|October 12, 2022
Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia studyAudrey Low, Maria A Prats-Sedano, Elizabeth McKiernan, et al.
Nature Communications|July 20, 2019
Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936Robert F Hillary, Daniel L McCartney, Sarah E Harris, et al.
Alzheimer'S Research & Therapy|August 1, 2018
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 3, 2025
Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p-tau in the earliest Alzheimer's continuum: Evidence across two independent cohortsRaffaele Cacciaglia, Carles Falcón, Gonzalo Sánchez Benavides, et al.
Pageof 15